LISURIDE MALEATE |
LISURIDE |
LYSURIDE |
REVANIL 200 |
(+)-LISURIDE |
N'-((8ALPHA)-9,10-DIDEHYDRO-6-METHYLERGOLIN-8-YL)-N,N-DIETHYLUREA |
DOPERGIN® |
LISURIDA |
LISURID |
LISURIDUM |
rxcui:6446 |
pubchem.compound:28864 |
chemidplus:18016-80-3 |
chembl:CHEMBL157138 |
drugbank:00589 |
FDA Approval | not approved by the FDA |
Drug Class | small molecule |
Drug Indications | Antiparkinson Agents |
Drug Class | antiparkinson agents |
Year of Approval | not approved by the fda |
Drug Groups | investigational |
Drug Categories | agents that produce hypertension |
Drug Categories | antidepressive agents |
Drug Categories | central nervous system depressants |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine antagonists |
Drug Categories | ergot alkaloids and derivatives |
Drug Categories | ergot-derivative dopamine receptor agonists |
Drug Categories | genito urinary system and sex hormones |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | prolactine inhibitors |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin receptor antagonists |
agonist (activating) |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
Trial Name | - |
agonist (activating) |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Specific Action of the Ligand | Partial agonist |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
Trial Name | - |
other/unknown |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
other/unknown |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
other/unknown |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
LISURIDE | DrugBank Drug Name |
18016-80-3 | CAS Number |
Arolac | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
LISURIDE | Primary Drug Name |
Year of Approval | not approved by the fda |
Drug Class | antiparkinson agents |
Drug Indications | Antiparkinson Agents |
Drug Class | small molecule |
FDA Approval | not approved by the FDA |
D0X7KB | TTD Drug ID |
LISURIDE | GuideToPharmacology Ligand Name |